Abstract
In a method of treating an inflammatory disease induced by a hyperimmune response, a composition is administered to a subject. The composition includes at least one of a chondrocyte and a cell capable of differentiating into a chondrocyte, and a cell into which a gene encoding TGF-β1 is introduced and derived from human embryonic kidney 293 (HEK-293) cell. The composition may be used for treating an inflammatory disease induced by a hyperimmune response.
Full Text
What is claimed is:
In a method of treating an inflammatory disease induced by a hyperimmune response, a composition is administered to a subject. The composition includes at least one of a chondrocyte and a cell capable of differentiating into a chondrocyte, and a cell into which a gene encoding TGF-β1 is introduced and derived from human embryonic kidney 293 (HEK-293) cell. The composition may be used for treating an inflammatory disease induced by a hyperimmune response.
Timeline
Filed
02/20/2026Published
06/18/2026Granted
Not AvailableIPC Codes(5)
A61K 35/32:Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
A61K 38/00:Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K 31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K 31/00; ergoline-based peptides A61K 31/48; containing macromolecular compounds having statistically distributed amino acid units A61K 31/74; medicinal preparations containing antigens or antibodies A61K 39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K 47/00)
A61P 29/00:Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]